{"id":"cyclopentolate","rwe":[{"pmid":"41867375","year":"2025","title":"Pseudomyopia and cycloplegic changes in young cynomolgus macaques.","finding":"","journal":"Molecular vision","studyType":"Clinical Study"},{"pmid":"41696457","year":"2026","title":"Comparative Analysis of the Efficacy of 1% Tropicamide and 1% Cyclopentolate Eye Drops for Cycloplegic Refraction in Indonesian Paediatric Population.","finding":"","journal":"The British and Irish orthoptic journal","studyType":"Clinical Study"},{"pmid":"41671150","year":"2026","title":"At-Home Pupil Dilation During the COVID-19 Pandemic in the Pediatric Population.","finding":"","journal":"Journal of pediatric ophthalmology and strabismus","studyType":"Clinical Study"},{"pmid":"41572986","year":"2026","title":"Pharmacological and light-driven pupillary accommodation in guinea pigs: comparative effects of muscarinic modulators and illumination across developmental stages.","finding":"","journal":"International journal of ophthalmology","studyType":"Clinical Study"},{"pmid":"41525096","year":"2026","title":"Efficacy of Topical Nepafenac Versus Nepafenac With Perioperative Cyclopentolate for Pain Management After Photorefractive Keratectomy: A Comparative Clinical Evaluation.","finding":"","journal":"Journal of refractive surgery (Thorofare, N.J. : 1995)","studyType":"Clinical Study"}],"_fda":{"id":"2fc4fc5f-9c4a-456e-9476-7791f6f9c3c1","set_id":"1d008c76-7210-4ace-90fa-7cd22762e12e","openfda":{"upc":["0300650396059"],"unii":["736I6971TE"],"route":["OPHTHALMIC"],"rxcui":["1298066","1298070","1298072","1298356","1298364","1298366"],"spl_id":["2fc4fc5f-9c4a-456e-9476-7791f6f9c3c1"],"brand_name":["Cyclogyl"],"spl_set_id":["1d008c76-7210-4ace-90fa-7cd22762e12e"],"package_ndc":["0065-0395-15","0065-0396-02","0065-0396-05","0065-0396-15","0065-0397-02","0065-0397-05","0065-0397-15"],"product_ndc":["0065-0395","0065-0396","0065-0397"],"generic_name":["CYCLOPENTOLATE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CYCLOPENTOLATE HYDROCHLORIDE"],"manufacturer_name":["Alcon Laboratories, Inc."],"application_number":["ANDA084109","ANDA084110","ANDA084108"],"is_original_packager":[true]},"version":"15","warnings":["WARNINGS: FOR TOPICAL OPHTHALMIC USE ONLY . NOT FOR INJECTION. This preparation may cause Central Nervous System (CNS) disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% CYCLOGYL solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes following instillation. Mydriatics may produce a transient elevation of intraocular pressure. Therefore, patients with untreated narrow angle glaucoma or anatomically narrow angles may be susceptible to angle closure following administration."],"pregnancy":["Pregnancy: Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE: Excessive dosage may produce behavioral disturbances, tachycardia, hyperpyrexia, hypertension, elevated intraocular pressure, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Patients exhibiting signs of overdosage should receive supportive care and monitoring."],"description":["Rx Only DESCRIPTION: CYCLOGYL ® (cyclopentolate hydrochloride ophthalmic solution, USP) is an anticholinergic prepared as a sterile, borate buffered, solution for topical ocular use. It is supplied in three strengths. The active ingredient is represented by the structural formula: Each mL of CYCLOGYL ® (cyclopentolate hydrochloride ophthalmic solution, USP) contains: Active: cyclopentolate hydrochloride 0.5%, 1% or 2%. Preservative: benzalkonium chloride 0.01%. Inactives: boric acid, edetate disodium, potassium chloride (except 2% strength), sodium carbonate and/or hydrochloric acid (to adjust pH), purified water. The pH range is between 3.0 and 5.5. chemical"],"precautions":["PRECAUTIONS: General: The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down's syndrome. Information for Patients: Do not touch dropper tip to any surface, as this may contaminate the solution. A transient burning sensation may occur upon instillation. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for 4 hours after examination. Drug Interactions: Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors. Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies in animals or humans have not been conducted to evaluate the carcinogenic potential of CYCLOGYL ® (cyclopentolate hydrochloride ophthalmic solution, USP). Pregnancy: Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed. Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cyclopentolate hydrochloride is administered to a nursing woman. Pediatric Use: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. Feeding intolerance and necrotizing enterocolitis (NEC) in preterm infants may follow ophthalmic use of this product. Cases of NEC have been reported in preterm infants following administration; however, causality has not been established. It is recommended that feeding be withheld for four (4) hours after examination. Observe infants closely for at least 30 minutes (see WARNINGS). Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"how_supplied":["HOW SUPPLIED: In multiple-dose plastic DROP-TAINER® dispensers: 0.5% CYCLOGYL 1% CYCLOGYL 2% CYCLOGYL 15 mL NDC 0065-0395-15 2 mL NDC 0065-0396-02 2 mL NDC 0065-0397-02 5 mL NDC 0065-0396-05 5 mL NDC 0065-0397-05 15 mL NDC 0065-0396-15 15 mL NDC 0065-0397-15 Storage: Store at 8°C to 25°C (46°F to 77°F). After opening, Cyclogyl can be used until the expiration date on the bottle."],"geriatric_use":["Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"pediatric_use":["Pediatric Use: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. Feeding intolerance and necrotizing enterocolitis (NEC) in preterm infants may follow ophthalmic use of this product. Cases of NEC have been reported in preterm infants following administration; however, causality has not been established. It is recommended that feeding be withheld for four (4) hours after examination. Observe infants closely for at least 30 minutes (see WARNINGS)."],"effective_time":"20240625","adverse_reactions":["ADVERSE REACTIONS: Ocular: Increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae have been reported. Non-ocular: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in children, especially with 2% concentration. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. This drug produces reactions similar to those of other anticholinergic drugs, but the central nervous system manifestations as noted above are more common. Other toxic manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include coma, medullary paralysis and death."],"contraindications":["CONTRAINDICATIONS: Should not be used if the patient is hypersensitive to any component of this preparation."],"drug_interactions":["Drug Interactions: Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors."],"general_precautions":["General: The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down's syndrome."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY: This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides."],"indications_and_usage":["INDICATIONS AND USAGE: Cyclopentolate hydrochloride is used to produce mydriasis and cycloplegia."],"information_for_patients":["Information for Patients: Do not touch dropper tip to any surface, as this may contaminate the solution. A transient burning sensation may occur upon instillation. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for 4 hours after examination."],"spl_unclassified_section":["© 2021 Alcon Inc. Revised: November 2021 ALCON LABORATORIES, INC. Fort Worth, Texas 76134 300051372-1121"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION: Adults: Instill one or two drops of 0.5%, 1% or 2% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days. Children: Instill one or two drops of 0.5%, 1% or 2% solution in the eye which may be repeated five to ten minutes later by a second application of 0.5% or 1% solution if necessary. Small Infants: A single instillation of one drop of 0.5% in the eye. To minimize absorption, apply pressure over the nasolacrimal sac for two to three minutes. Observe infant closely for at least 30 minutes following instillation. Individuals with heavily pigmented irides may require higher strengths."],"spl_product_data_elements":["Cyclogyl cyclopentolate hydrochloride CYCLOPENTOLATE HYDROCHLORIDE CYCLOPENTOLATE BENZALKONIUM CHLORIDE BORIC ACID EDETATE DISODIUM SODIUM CARBONATE HYDROCHLORIC ACID WATER POTASSIUM CHLORIDE Cyclogyl cyclopentolate hydrochloride CYCLOPENTOLATE HYDROCHLORIDE CYCLOPENTOLATE BENZALKONIUM CHLORIDE BORIC ACID EDETATE DISODIUM SODIUM CARBONATE HYDROCHLORIC ACID WATER POTASSIUM CHLORIDE Cyclogyl cyclopentolate hydrochloride CYCLOPENTOLATE HYDROCHLORIDE CYCLOPENTOLATE BENZALKONIUM CHLORIDE BORIC ACID EDETATE DISODIUM SODIUM CARBONATE HYDROCHLORIC ACID WATER logo carton label carton label carton label"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 0065-0395-15 Alcon Cyclogyl ® 0.5% (cyclopentolate hydrochloride ophthalmic solution, USP) 15 mL Sterile INGREDIENTS: Each mL contains: Active: cyclopentolate hydrochloride 0.5%. Preservative: benzalkonium chloride 0.01%. Inactives: boric acid, edetate disodium, potassium chloride, sodium carbonate and/or hydrochloric acid (to adjust pH), purified water. The pH range is between 3.0 and 5.5. FOR TOPICAL OPHTHALMIC USE ONLY. Rx Only USUAL DOSAGE: Instill one or two drops in the eye which can be repeated in five to ten minutes. Read enclosed insert. PRECAUTION: Do not touch dropper tip to any surface, as this may contaminate the solution. STORAGE: Store at 8° to 25°C (46°-77°F). After opening Cyclogyl can be used until the expiration date on the bottle. ALCON ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA Product of Spain 300037981-0520 SN: LOT: EXP.: GTIN: 00300650395151 NDC 0065-0395-15 Alcon Cyclogyl ® 0.5% (cyclopentolate hydrochloride ophthalmic solution, USP) Sterile 15 mL Rx Only INGREDIENTS: Each mL contains : Active: cyclopentolate hydrochloride 0.5%. Preservative: benzalkonium chloride 0.01%. Inactives: boric acid, edetate disodium, potassium chloride, sodium carbonate and/or hydrochloric acid (to adjust pH), purified water. The pH range is between 3.0 and 5.5. PRECAUTION: Do not touch dropper tip to any surface, as this may contaminate the solution. FOR TOPICAL OPHTHALMIC USE ONLY USUAL DOSAGE: Instill one or two drops in the eye which can be repeated in five to ten minutes if necessary. Read enclosed insert. STORAGE: Store at 8° to 25°C (46° to 77°F). ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA Printed in USA 300037980-0520 LOT: EXP.: NDC 0065-0396-05 Alcon Cyclogyl ® 1% (cyclopentolate hydrochloride ophthalmic solution, USP) 5 mL Sterile INGREDIENTS: Each mL contains : Active: cyclopentolate hydrochloride 1%. Preservative: benzalkonium chloride 0.01%. Inactives: boric acid, edetate disodium, potassium chloride, sodium carbonate and/or hydrochloric acid (to adjust pH), purified water. The pH range is between 3.0 and 5.5. Rx Only USUAL DOSAGE: Instill one or two drops in the eye which can be repeated in five to ten minutes if necessary. Read enclosed Insert. PRECAUTION: Do not touch dropper tip to any surface, as this may contaminate the solution. STORAGE: Store at 8° to 25°C (46° to 77°F). After opening, Cyclogyl can be used until the expiration date on the bottle. FOR TOPICAL OPHTHALMIC USE ONLY. Alcon ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA Product of Spain Printed in the USA 300037979 -0520 SN: LOT: EXP.: GTIN: 00300650396059 NDC 0065-0396-05 Alcon Cyclogyl ® 1% (cyclopentolate hydrochloride ophthalmic solution, USP) Sterile 5 mL Rx Only INGREDIENTS: Each mL contains : Active: cyclopentolate hydrochloride 1%. Preservative: benzalkonium chloride 0.01%. Inactives: boric acid, edetate disodium, potassium chloride, sodium carbonate and/or hydrochloric acid (to adjust pH), purified water. The pH range is between 3.0 and 5.5. PRECAUTION: Do not touch dropper tip to any surface, as this may contaminate the solution. USUAL DOSAGE: Instill one or two drops in the eye which can be repeated in five to ten minutes if necessary. Read enclosed insert. STORAGE: Store at 8° to 25°C (46° to 77°F). ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA Printed in USA LOT EXP.: 300037978-0520 NDC 0065-0397-15 Alcon Cyclogyl ® 2% (cyclopentolate hydrochloride ophthalmic solution, USP) 15 mL Sterile Rx Only USUAL DOSAGE: Instill one or two drops in the eye which can be repeated in five to ten minutes if necessary. Read enclosed insert. PRECAUTION: Do not touch dropper tip to any surface, as this may contaminate the solution. STORAGE: Store at 8° to 25°C (46° to 77°F). After opening, Cyclogyl can be used until the expiration date on the bottle. INGREDIENTS: Each mL contains : Active: cyclopentolate hydrochloride 2%. Preservative: benzalkonium chloride 0.01%. Inactives: boric acid, edetate disodium, sodium carbonate and/or hydrochloric acid (to adjust pH), purified water. The pH range is between 3.0 and 5.5. FOR TOPICAL OPHTHALMIC USE ONLY. Alcon ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA Product of Spain Printed in USA 300037977-0520 SN: LOT: EXP.: GTIN: 00300650397155 NDC 0065-0397-15 Alcon Cyclogyl ® 2% (cyclopentolate hydrochloride ophthalmic solution, USP) Sterile 15 mL Rx Only INGREDIENTS: Each mL contains : Active: cyclopentolate hydrochloride 2%. Preservative: benzalkonium chloride 0.01%. Inactives: boric acid, edetate disodium, sodium carbonate and/or hydrochloric acid (to adjust pH), purified water. The pH range is between 3.0 and 5.5. PRECAUTION: Do not touch dropper tip to any surface, as this may contaminate the solution. USUAL DOSAGE: Instill one or two drops in the eye which can be repeated in five to ten minutes if necessary. Read enclosed Insert. STORAGE: Store at 8° to 25°C (46° to 77°F). ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA Printed in USA LOT: EXP.: 300037975-0520"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies in animals or humans have not been conducted to evaluate the carcinogenic potential of CYCLOGYL ® (cyclopentolate hydrochloride ophthalmic solution, USP)."]},"tags":[{"label":"cyclopentolate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Muscarinic acetylcholine receptor M3","category":"target"},{"label":"CHRM3","category":"gene"},{"label":"S01FA04","category":"atc"},{"label":"Ophthalmic","category":"route"},{"label":"Solution","category":"form"},{"label":"Solution/ Drops","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Cycloplegia","category":"indication"},{"label":"Dilated pupil","category":"indication"},{"label":"Perioperative Mydriasis","category":"indication"},{"label":"Alcon Labs Inc","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinergic Antagonists","category":"pharmacology"},{"label":"Muscarinic Antagonists","category":"pharmacology"},{"label":"Mydriatics","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"EYE PAIN","source":"FDA FAERS","actionTaken":"59 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"48 reports"},{"date":"","signal":"VISION BLURRED","source":"FDA FAERS","actionTaken":"42 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"41 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"40 reports"},{"date":"","signal":"APNOEA","source":"FDA FAERS","actionTaken":"36 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"36 reports"},{"date":"","signal":"OCULAR HYPERAEMIA","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"VISUAL IMPAIRMENT","source":"FDA FAERS","actionTaken":"33 reports"},{"date":"","signal":"TOXIC ANTERIOR SEGMENT SYNDROME","source":"FDA FAERS","actionTaken":"32 reports"}],"commonSideEffects":[{"effect":"Seizures","drugRate":"reported","severity":"unknown"},{"effect":"Coma","drugRate":"reported","severity":"unknown"},{"effect":"Medullary paralysis","drugRate":"reported","severity":"unknown"},{"effect":"Death","drugRate":"reported","severity":"unknown"},{"effect":"Hallucinations","drugRate":"reported","severity":"unknown"},{"effect":"Hyperactivity","drugRate":"reported","severity":"unknown"},{"effect":"Disorientation as to time and place","drugRate":"reported","severity":"unknown"},{"effect":"Failure to recognize people","drugRate":"reported","severity":"unknown"},{"effect":"Ataxia","drugRate":"reported","severity":"unknown"},{"effect":"Incoherent speech","drugRate":"reported","severity":"unknown"},{"effect":"Restlessness","drugRate":"reported","severity":"unknown"},{"effect":"Tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"Hyperpyrexia","drugRate":"reported","severity":"unknown"},{"effect":"Vasodilation","drugRate":"reported","severity":"unknown"},{"effect":"Urinary retention","drugRate":"reported","severity":"unknown"},{"effect":"Diminished gastrointestinal motility","drugRate":"reported","severity":"unknown"},{"effect":"Decreased secretion in salivary and sweat glands","drugRate":"reported","severity":"unknown"},{"effect":"Pharynx","drugRate":"reported","severity":"unknown"},{"effect":"Bronchi","drugRate":"reported","severity":"unknown"},{"effect":"Nasal passages","drugRate":"reported","severity":"unknown"},{"effect":"Skin rash","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal distention in infants","drugRate":"reported","severity":"unknown"},{"effect":"Unusual drowsiness","drugRate":"reported","severity":"unknown"},{"effect":"Blepharoconjunctivitis","drugRate":"reported","severity":"unknown"},{"effect":"Punctate keratitis","drugRate":"reported","severity":"unknown"},{"effect":"Synechiae","drugRate":"reported","severity":"unknown"},{"effect":"Hyperemia","drugRate":"reported","severity":"unknown"},{"effect":"Irritation","drugRate":"reported","severity":"unknown"},{"effect":"Burning","drugRate":"reported","severity":"unknown"}],"contraindications":["Angle-closure glaucoma","Arterial aneurysm","Arteriosclerotic vascular disease","Benign prostatic hyperplasia","Brain damage","Complete trisomy 21 syndrome","Conduction disorder of the heart","Diabetes mellitus","Disorder of coronary artery","Heart disease","Hypertensive disorder","Hyperthyroidism","Predisposition to Glaucoma","Spastic paralysis"],"specialPopulations":{"Pregnancy":"Cyclopentolate should be administered to pregnant woman only if clearly needed.","Geriatric use":"In the elderly and others where increased intraocular pressure may be encountered, mydriatics and cycloplegics should be used cautiously.","Paediatric use":"Increased susceptibility to cyclopentolate has been reported in pediatric patients with spastic paralysis or brain damage. Therefore, cyclopentolate should be used with great caution in these patients. Feeding intolerance may follow ophthalmic use of this product in neonates. It is recommended that feeding be withheld for four (4) hours after examination. Do not use concentrations higher than 0.5% in small infants (see WARNINGS)."}},"trials":[],"aliases":[],"company":"Alcon Labs Inc","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.3482/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$485","description":"CYCLOPENTOLATE 1% EYE DROP","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CYCLOPENTOLATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:49:48.383134+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:49:53.685429+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:49:47.302924+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:37.899408+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:37.899434+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:49:55.576289+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201338/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:49:54.667401+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA084109, ANDA084110, ANDA084108","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:37.899439+00:00"}},"allNames":"cyclogyl","offLabel":[],"synonyms":["cyclopentolate","cyclopentolate hydrochloride","cyclogyl","cyclopentylate","cyclopentolate HCl"],"timeline":[{"date":"1974-07-31","type":"positive","source":"DrugCentral","milestone":"FDA approval (Alcon Labs Inc)"}],"aiSummary":"Cyclogyl (Cyclopentolate) is a small molecule drug developed by Alcon Labs Inc, targeting the muscarinic acetylcholine receptor M3. It is a cyclopentolate drug class, approved by the FDA in 1974 for indications such as cycloplegia, dilated pupil, and perioperative mydriasis. Cyclogyl is off-patent, with 8 generic manufacturers available. As a muscarinic receptor antagonist, it works by blocking the action of acetylcholine, leading to pupil dilation and paralysis of accommodation. Key safety considerations include potential systemic effects and interactions with other medications.","approvals":[{"date":"1974-07-31","orphan":false,"company":"ALCON LABS INC","regulator":"FDA"}],"brandName":"Cyclogyl","ecosystem":[{"indication":"Cycloplegia","otherDrugs":[{"name":"homatropine","slug":"homatropine","company":""},{"name":"scopolamine","slug":"scopolamine","company":"Novartis"},{"name":"tropicamide","slug":"tropicamide","company":""}],"globalPrevalence":null},{"indication":"Dilated pupil","otherDrugs":[{"name":"hydroxyamfetamine","slug":"hydroxyamfetamine","company":"Pharmics"},{"name":"phenylephrine","slug":"phenylephrine","company":"Ani Pharms"},{"name":"scopolamine","slug":"scopolamine","company":"Novartis"},{"name":"tropicamide","slug":"tropicamide","company":""}],"globalPrevalence":null},{"indication":"Perioperative Mydriasis","otherDrugs":[{"name":"atropine","slug":"atropine","company":"Gd Searle Llc"},{"name":"homatropine","slug":"homatropine","company":""},{"name":"scopolamine","slug":"scopolamine","company":"Novartis"},{"name":"tropicamide","slug":"tropicamide","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Muscarinic acetylcholine receptor M3","novelty":"Follow-on","targets":[{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"}],"modality":"Small Molecule","drugClass":"cyclopentolate","explanation":"","oneSentence":"","technicalDetail":"Cyclopentolate acts as a competitive antagonist at the muscarinic acetylcholine receptor M3, inhibiting the parasympathetic stimulation of the iris sphincter and ciliary muscles, resulting in mydriasis and cycloplegia."},"commercial":{"launchDate":"1974","_launchSource":"DrugCentral (FDA 1974-07-31, ALCON LABS INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/757","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CYCLOPENTOLATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYCLOPENTOLATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:25:14.480867","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:49:58.011134+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"atropine","drugSlug":"atropine","fdaApproval":"1960-09-15","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"scopolamine","drugSlug":"scopolamine","fdaApproval":"1979-12-31","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"methscopolamine","drugSlug":"methscopolamine","fdaApproval":"1953-04-09","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"homatropine","drugSlug":"homatropine","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tropicamide","drugSlug":"tropicamide","fdaApproval":"1960-02-23","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"cyclopentolate","indications":{"approved":[{"name":"Cycloplegia","source":"DrugCentral","snomedId":68158006,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Dilated pupil","source":"DrugCentral","snomedId":37125009,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Perioperative Mydriasis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"}],"offLabel":[{"name":"Prevention of Posterior Synechiae","source":"DrugCentral","drugName":"CYCLOPENTOLATE","evidenceCount":3,"evidenceLevel":"emerging"},{"name":"Uveitis","source":"DrugCentral","drugName":"CYCLOPENTOLATE","evidenceCount":43,"evidenceLevel":"moderate"}],"pipeline":[]},"drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"atropine","brandName":"atropine","genericName":"atropine","approvalYear":"1960","relationship":"same-class"},{"drugId":"scopolamine","brandName":"scopolamine","genericName":"scopolamine","approvalYear":"1979","relationship":"same-class"},{"drugId":"methscopolamine","brandName":"methscopolamine","genericName":"methscopolamine","approvalYear":"1953","relationship":"same-class"},{"drugId":"homatropine","brandName":"homatropine","genericName":"homatropine","approvalYear":"","relationship":"same-class"},{"drugId":"tropicamide","brandName":"tropicamide","genericName":"tropicamide","approvalYear":"1960","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06885242","phase":"PHASE4","title":"Efficacy and Safety of Cyclopentolate Microdrops for Cycloplegic Refraction in Children","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2024-09-06","conditions":["Cycloplegic Refraction"],"enrollment":63,"completionDate":"2025-10-08"},{"nctId":"NCT07012512","phase":"NA","title":"Adjusted Study Protocol: Within-Subject Paired-Eye Design Comparing Pilocarpine 0.1%, Phentolamine 0.75%, and Combination Therapy for Cyclopentolate Reversal in Children","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-06-01","conditions":["Pupillary Constriction","Accomodation"],"enrollment":60,"completionDate":"2025-12-30"},{"nctId":"NCT06914063","phase":"NA","title":"Assessing Patient Comfort, Anxiety, and Satisfaction During CR Comparing Conventional Drops With ROC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Superior University","startDate":"2025-03-20","conditions":["Cycloplegic Paralysis of Accommodation"],"enrollment":74,"completionDate":"2026-02-20"},{"nctId":"NCT03375996","phase":"","title":"Evaluation of a Protocol of Pupil Dilation Before Laser-assisted Cataract Surgery","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2018-06-01","conditions":["Cataract Surgery"],"enrollment":60,"completionDate":"2024-08-21"},{"nctId":"NCT06077682","phase":"PHASE4","title":"Cycloplegic Refraction in Pediatric Patients With Esotropia","status":"UNKNOWN","sponsor":"Islamic Hospital, Jordan","startDate":"2023-09-01","conditions":["Cycloplegia","Refractive Errors","Esotropia","Vision Disorders"],"enrollment":100,"completionDate":"2024-12-01"},{"nctId":"NCT05927740","phase":"NA","title":"The Efficacy of Hyperemesis Gravidarum on Macular Thickness, Corneal Thickness and Intraocular Pressure in Pregnancy","status":"COMPLETED","sponsor":"Batman Training and Research Hospital","startDate":"2020-03-10","conditions":["Corneal Dystrophy","Macular Dystrophy","Hyperemesis Gravidarum - Severe"],"enrollment":110,"completionDate":"2023-05-11"},{"nctId":"NCT05781997","phase":"","title":"Prevalence of Refractive Errors in Primary School Children","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-05-01","conditions":["Refractive Errors"],"enrollment":500,"completionDate":"2023-09"},{"nctId":"NCT05614622","phase":"NA","title":"Mydriatic Drops After Combined Surgery","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2020-11-10","conditions":["Posterior Synechiae of Iris"],"enrollment":60,"completionDate":"2022-01-03"},{"nctId":"NCT05442801","phase":"PHASE4","title":"Cycloplegic Refraction Among Children","status":"COMPLETED","sponsor":"Islamic Hospital, Jordan","startDate":"2022-03-01","conditions":["Cycloplegia"],"enrollment":55,"completionDate":"2022-06-20"},{"nctId":"NCT05204069","phase":"NA","title":"Screening for 3-D Visual Disorders in Preschool Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-01-01","conditions":["Amblyopia","Strabismus","Anisometropia"],"enrollment":95,"completionDate":"2021-09-01"},{"nctId":"NCT00748059","phase":"PHASE1","title":"The Pathophysiology of Orthostatic Hypotension","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"1996-12","conditions":["Autonomic Nervous System Diseases","Orthostatic Hypotension","Dopamine Beta-Hydroxylase Deficiency","Orthostatic Intolerance"],"enrollment":10,"completionDate":"2020-12"},{"nctId":"NCT04838665","phase":"PHASE4","title":"Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study","status":"COMPLETED","sponsor":"University of the Philippines","startDate":"2011-09-30","conditions":["Retinopathy of Prematurity"],"enrollment":60,"completionDate":"2011-09-30"},{"nctId":"NCT02717871","phase":"PHASE3","title":"Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":["Keratitis; Infectious Disease (Manifestation)"],"enrollment":35,"completionDate":"2020-10"},{"nctId":"NCT04396301","phase":"PHASE3","title":"Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco","status":"COMPLETED","sponsor":"Cairo University","startDate":"2019-02-01","conditions":["Corneal Endothelial Cell Loss","Mydriasis","Cataract"],"enrollment":30,"completionDate":"2019-09-30"},{"nctId":"NCT02909140","phase":"NA","title":"Optimal Method for Mydriasis in Cataract Surgery","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2016-09","conditions":["Cataract"],"enrollment":3,"completionDate":"2018-08-15"},{"nctId":"NCT03851172","phase":"PHASE2","title":"Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03-01","conditions":["Cataract","Miosis"],"enrollment":75,"completionDate":"2020-03-30"},{"nctId":"NCT03638726","phase":"PHASE4","title":"Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification","status":"UNKNOWN","sponsor":"Dar El Oyoun Hospital","startDate":"2018-09-28","conditions":["Cataract","Mydriasis","Adverse Drug Event"],"enrollment":40,"completionDate":"2019-06"},{"nctId":"NCT02459600","phase":"EARLY_PHASE1","title":"Comparison of Refraction Measurments in Children Under General Anesthesia, With and Without Cycloplegic Drops","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2015-05","conditions":["General Anesthesia"],"enrollment":20,"completionDate":"2016-05"},{"nctId":"NCT01170130","phase":"NA","title":"Lidocaine Usage for Pupil Dilatation (Mydriasis)","status":"COMPLETED","sponsor":"Carmel Medical Center","startDate":"2009-12","conditions":["Cataract"],"enrollment":100,"completionDate":"2012-10"},{"nctId":"NCT02177539","phase":"PHASE4","title":"A New More Efficient Cycloplegia Scheme","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2014-05","conditions":["Refractive Errors"],"enrollment":30,"completionDate":"2014-09"},{"nctId":"NCT00348166","phase":"PHASE1","title":"Does Undercorrection of Myopia Retard Myopia Progression Among Kindergarten Children?","status":"WITHDRAWN","sponsor":"KK Women's and Children's Hospital","startDate":"2005-12","conditions":["Refractive Error - Myopia"],"enrollment":180,"completionDate":"2008-06"},{"nctId":"NCT01169688","phase":"NA","title":"Preoperative Cataract Pupillary Dilation: Inpatient At The Ambulatory Surgery Center vs Outpatient Dilation Prior To Arrival At The Ambulatory Surgery Center","status":"COMPLETED","sponsor":"Northwest Kansas Surgery Center","startDate":"2007-12","conditions":["Pupil Dilation Prior to Cataract Surgery In-patient","Pupil Dilation Prior to Cataract Surgery Out-patient"],"enrollment":50,"completionDate":"2008-04"},{"nctId":"NCT01054027","phase":"NA","title":"Study on Effective Mydriasis in Premature Infants","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-03","conditions":["Retinopathy of Prematurity (ROP)"],"enrollment":15,"completionDate":"2008-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Ophthalmic","formulation":"Solution, Solution/ Drops","formulations":[{"form":"SOLUTION","route":"OPHTHALMIC","productName":"Cyclopentolate Hydrochloride"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"AK-PENTOLATE"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Cyclogyl"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Cyclomydril"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Cyclopentolate"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Cyclopentolate Hydrochloride"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147792","MMSL":"225","NDDF":"001752","UNII":"I76F4SHP7J","VUID":"4019700","CHEBI":"CHEBI:4024","VANDF":"4018593","INN_ID":"266","RXNORM":"106029","UMLSCUI":"C0010582","chemblId":"CHEMBL1201338","ChEMBL_ID":"CHEMBL1201338","KEGG_DRUG":"D01002","DRUGBANK_ID":"DB00979","PUBCHEM_CID":"2905","SNOMEDCT_US":"372869004","IUPHAR_LIGAND_ID":"7153","SECONDARY_CAS_RN":"5870-29-1","MESH_DESCRIPTOR_UI":"D003519"},"formularyStatus":[],"originalProduct":{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","company":"Alcon Laboratories, Inc.","brandName":"Cyclogyl","isOriginal":true,"marketingStatus":"ANDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1974-","companyName":"Alcon Labs Inc","relationship":"Original Developer"}],"publicationCount":630,"therapeuticAreas":["Ophthalmology"],"atcClassification":{"source":"DrugCentral","atcCode":"S01FA04","allCodes":["S01FA04","S01FA54"]},"biosimilarFilings":[],"originalDeveloper":"Alcon Labs Inc","recentPublications":[{"date":"2025","pmid":"41867375","title":"Pseudomyopia and cycloplegic changes in young cynomolgus macaques.","journal":"Molecular vision"},{"date":"2026","pmid":"41696457","title":"Comparative Analysis of the Efficacy of 1% Tropicamide and 1% Cyclopentolate Eye Drops for Cycloplegic Refraction in Indonesian Paediatric Population.","journal":"The British and Irish orthoptic journal"},{"date":"2026 Feb 10","pmid":"41671150","title":"At-Home Pupil Dilation During the COVID-19 Pandemic in the Pediatric Population.","journal":"Journal of pediatric ophthalmology and strabismus"},{"date":"2026","pmid":"41572986","title":"Pharmacological and light-driven pupillary accommodation in guinea pigs: comparative effects of muscarinic modulators and illumination across developmental stages.","journal":"International journal of ophthalmology"},{"date":"2026 Jan","pmid":"41525096","title":"Efficacy of Topical Nepafenac Versus Nepafenac With Perioperative Cyclopentolate for Pain Management After Photorefractive Keratectomy: A Comparative Clinical Evaluation.","journal":"Journal of refractive surgery (Thorofare, N.J. : 1995)"}],"companionDiagnostics":[],"genericManufacturers":8,"_genericFilersChecked":true,"genericManufacturerList":["Alcon Labs Inc","Alcon Pharms Ltd","Bausch And Lomb","Epic Pharma Llc","Pharmafair","Rising","Sciegen Pharms","Sola Barnes Hind"],"status":"approved","companyName":"Alcon Labs Inc","companyId":"alcon-labs-inc","modality":"Small molecule","firstApprovalDate":"1974","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1974-07-31T00:00:00.000Z","mah":"ALCON LABS INC","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1991-02-20T00:00:00.000Z","mah":"ALCON LABS INC","brand_name_local":null,"application_number":"ANDA084109"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-12-24T00:00:00.000Z","mah":"ALCON LABS INC","brand_name_local":null,"application_number":"ANDA084300"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1998-02-10T00:00:00.000Z","mah":"BAUSCH AND LOMB","brand_name_local":null,"application_number":"ANDA040075"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1998-12-09T00:00:00.000Z","mah":"ALCON LABS INC","brand_name_local":null,"application_number":"ANDA084110"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-04-28T00:00:00.000Z","mah":"ALCON LABS INC","brand_name_local":null,"application_number":"ANDA084108"},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:49:58.011134+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}